Greylin Investment Mangement Inc. Sells 4,500 Shares of Johnson & Johnson (NYSE:JNJ)

Greylin Investment Mangement Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,974 shares of the company’s stock after selling 4,500 shares during the period. Johnson & Johnson makes up 3.1% of Greylin Investment Mangement Inc.’s portfolio, making the stock its 9th biggest position. Greylin Investment Mangement Inc.’s holdings in Johnson & Johnson were worth $13,064,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after purchasing an additional 1,627,370 shares in the last quarter. Phocas Financial Corp. boosted its position in shares of Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $174,342,000 after purchasing an additional 125,161,066 shares in the last quarter. Northern Trust Corp boosted its position in shares of Johnson & Johnson by 0.9% during the 2nd quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock valued at $4,910,381,000 after purchasing an additional 313,073 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Johnson & Johnson by 11.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after purchasing an additional 2,204,757 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock valued at $2,784,913,000 after purchasing an additional 122,033 shares in the last quarter. 72.01% of the stock is currently owned by hedge funds and other institutional investors.

JNJ has been the subject of several research reports. Barclays initiated coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price objective for the company. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley restated an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Bank of America restated a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $151.00.

Shares of JNJ opened at $131.33 on Friday. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a 50-day moving average of $129.92 and a two-hundred day moving average of $134.97. The stock has a market cap of $341.03 billion, a price-to-earnings ratio of 14.85, a PEG ratio of 2.18 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. During the same period last year, the company posted $2.10 earnings per share. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 8.59 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Why do analysts give a neutral rating?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.